Biotech Startups

AI Metrics builds AI-enabled radiology software that assists radiologists in reading and reporting on cancer imaging, reducing read times and generating automated patient reports. The product targets radiologists and healthcare organizations to improve accuracy and reduce workflow burnout.

1 investor

Chemlex designs chemical synthesis routes and evaluates ESG-related factors such as energy consumption, atom economy, and hazardous chemical waste to quantitatively rank routes and deliver more environmentally friendly options to clients. It uses AI models trained on internally initiated projects and dedicated client servers.

1 investor

Aiffinity develops an AI–NMR platform for drug discovery, supporting fragment screening, hit discovery, lead optimization, and NMR-based protein structure determination, including for intrinsically disordered proteins. Its technology targets challenging or "undruggable" protein targets for pharmaceutical and biotech research.

1 investor

Aila Biotech develops brain-targeted AAV gene therapy that enables the central nervous system to locally produce immune-modulating biologics, aiming to reduce chronic neuroinflammation while limiting systemic exposure. Its lead programme, AILA-001, targets primary progressive multiple sclerosis with potential expansion to other CNS inflammatory indications.

1 investor

Aileens Pharma researches skin microbiome modulation and interkingdom communication to develop therapeutic applications. The company focuses on targeted skin microbiome technology for therapeutic use.

1 investor

AIN Medicare is a Malaysian pharmaceutical manufacturer producing intravenous and sterile solutions, including large and small volume parenterals, irrigation solutions, haemodialysis concentrates, and peritoneal dialysis solutions. The company has operated in Malaysia since 1993.

1 investor

ÄIO develops sustainable alternatives to animal fats and palm oil using proprietary microbial lipid technology for the oleochemical industry. The company converts agricultural and food industry side streams through fermentation-based biotechnology to produce ingredients for cosmetics and specialty chemicals.

1 investor

Airiver Medical is a clinical-stage company developing a Drug Coated Balloon to treat respiratory tract conditions such as airway stenosis and chronic sinus inflammation. The investigational device aims to create sustained patency with better outcomes and fewer treatments for patients with these conditions.

1 investor

Airway Therapeutics is a biotech company developing inhaled therapeutics for inflammatory and infectious lung diseases, including programs targeting bronchopulmonary dysplasia, acute respiratory distress syndrome, and pulmonary fibrosis.

1 investor

AirZyme develops biocatalyst technologies designed to improve the efficiency and scalability of carbon capture and removal systems, integrating them into industrial carbon capture setups. The company works at the intersection of biology, materials science, and engineering to support climate mitigation.

1 investor

AIVITA Biomedical is a biotechnology company developing personalized vaccines using an autologous cell therapy platform, including a pan-antigenic cancer vaccine that targets all neoantigens and a multi-pathogen vaccine kit for infectious disease prevention. Its work draws on expertise in stem cell growth and high-purity cell differentiation.

1 investor

Aizen is an AI-native biotechnology company that designs novel oral peptides using non-canonical amino acids and an AI platform called DaX to treat chronic immune disorders. The company develops both proprietary therapeutics and partners with biopharma companies to advance gut-restricted and systemic oral biologics.

1 investor

Ajaya Bio develops bispecific therapies designed to eliminate disease-driving cells while sparing healthy ones, using its BOLT-360 discovery platform built around hybrid binders, precise activation, and advanced linkers. The company operates in the biotherapeutics field.

1 investor

AKAN Biosciences is a biotechnology and cellular therapy company developing injectable, adipose stem cell-based regenerative products to treat degenerative diseases and injuries. Its lead product, StroMel, is in Phase 2 clinical trials for knee osteoarthritis, with additional trials planned for other joints, wound healing, Crohn's disease, sports injuries, and autism.

1 investor

Akanocure is a drug development company using a proprietary chemistry platform to create novel small-molecule therapies, with a focus on orphan and unmet needs in oncology and blocking metastatic processes. Its work spans chemical methodology development and classic drug discovery for cancer treatments.

1 investor

Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates (ADCs) built on a proprietary PH1 spliceosome-modulating payload that disrupts RNA splicing in cancer cells. Its pipeline includes AKTX-101, targeting the Trop2 receptor, and AKTX-102, targeting CEACAM5 across solid tumors.

1 investor

Akira Bio develops therapies for people living with sickle cell disease and other hemoglobinopathies. It is a biotechnology company focused on treatments for blood disorders.

1 investor

Akiram Therapeutics develops targeted radioimmunotherapy and radiopharmaceuticals to diagnose and treat solid tumors, aiming to deliver radioactivity to cancer cells while sparing healthy tissue. The company, with origins in Uppsala University research, is at a preclinical/clinical development stage in oncology.

1 investor

Akkure (Akkure Genomics) builds an AI- and genomics-based platform that matches cancer patients to suitable clinical trials and supports trial recruitment for oncology centres, charities, pharmacies, primary care, and hospitals. It operates as a GDPR/HIPAA-compliant clinical data company focused on precision oncology, giving patients control and ownership of their clinical data.

1 investor

Alastin is a scientific skincare brand offering clinically formulated products, including treatments for skin discoloration, hydrating and soothing formulations, and tinted sun protection, built around its proprietary TriHex Technology. Products are sold to consumers, who can connect with skincare providers for customized regimens.

1 investor

Alaunos Therapeutics is developing an oral small-molecule therapeutic for obesity and other metabolic disorders that does not rely on hormonal manipulation. The company has identified a lead compound in preclinical evaluation and is conducting studies to inform IND-enabling work.

1 investor

Albutec develops extracorporeal albumin dialysis (ECAD) technology, including its MaxiCycler device with redesigned adsorbent and tubing, to support or replace liver function in patients with acute and acute-on-chronic liver failure. The platform is intended for use by doctors, nurses, and critical care medical teams treating liver patients.

1 investor

Alchemedicine is a drug discovery company focused on research and development of new small-molecule medicines, using its proprietary synthesis technology HiSAP® to improve on existing drugs' weak efficacy, side effects, and pharmacokinetics. It pursues multiple simultaneous R&D programs across disease areas with high unmet medical need.

1 investor

Alchemi combines AI with scientific expertise to accelerate drug development timelines and reduce time-to-market for therapies. The company serves pharmaceutical development teams and aims to lower drug costs and improve access to medicines.

1 investor